[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-cv-risk\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-cv-risk":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,50,83,114,138,164,192,216,245,278,307,328,358,384,409,437,471,492,518,538,565,593,619,650,676],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100598123","improving-the-heart-health-of-home-health-aides-100598123",false,"NCT07067398","Improving the Heart Health of Home Health Aides","Improving the Cardiovascular Health of Home Health Aides","VITAL","Inclusion Criteria\n\nHome Health Aide Participants\n\n* Currently working as a home health aide\n* Speak English or Spanish\n* ≥ 18 years of age\n* Have low CV Health as assessed by LE8 components made up by physical health measurements (blood pressure, BMI) and general self-reported health (physical activity, diet, smoking, sleep); calculated to be a score of 0-50 (the total score ranges from 0-100)\n\nPeer Coach Participants\n\n* Previously participated in and completed Peer Coach training as part of the prior LE8 study (WCM IRB #24-11028134), or are members of the Weill Cornell Medicine study team who are trained in delivering the intervention.\n* Speak English or Spanish\n\nExclusion Criteria:\n\nHome Health Aide Participants\n\n* Less than 1 year of job experience as a home health aide\n* Does not possess a smartphone\n* Gotten dizzy before with a finger stick blood sugar\u002Fcholesterol test\n* Have a history of syncope with a finger stick blood sugar\u002Fcholesterol test\n\nPeer Coach Participants\n\n* Speak a language other than English or Spanish\n* Did not complete Peer Coach training as part of the prior LE8 study (WCM IRB #24-11028134), or are not members of the Weill Cornell Medicine study team who are trained in delivering the intervention.",true,"ALL","18 Years",{"count":22,"type":23},40,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this early-stage study is to support the heart health of home health aides, a workforce that provides care for adults at home but whose own health has been historically poor. To do this, the study will use Life's Essential 8 (LE8), a program developed by the American Heart Association (AHA) that promotes cardiovascular wellness through education and lifestyle changes. The program has been adapted specifically for home health aides and will be delivered by trained \"peer coaches,\" who are fellow home health aides who will help guide participants through the program.\n\nThe main questions the study aims to answer are:\n\n* Will the LE8 intervention, which provides cardiovascular health education and support with positive thinking, be used by home health aides and do they like it?\n* Does the LE8 intervention actually improve home health aides' cardiovascular health after the intervention's conclusion compared to baseline?\n\nParticipants will be paired with a trained peer coach and take part in the 10-week program over the course of 6 months. The program includes support for healthy behaviors and positive thinking, with the goal of making lasting improvements in cardiovascular health.",[29,30,31,32],"Cardiovascular","Cardiovascular (CV) Risk","Cardiovascular Disease (CVD) Risk Factors","Cardiovascular Health",[34,35,36],"cardiovascular health intervention","home health aide","peer coaching","RECRUITING","2026-08-18",{"date":40,"type":41},"2026-08-20","ACTUAL",{"date":43,"type":41},"2025-09-09",{"date":45,"type":23},"2026-10",{"name":47,"class":48},"Weill Medical College of Cornell University","OTHER",2,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":18,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100363602","geospatial-analysis-of-neighborhood-environmental-stress-in-relation-to-biological-markers-of-cardiovascular-health-and-health-behaviors-in-women-100363602","NCT04014348","Geospatial Analysis of Neighborhood Environmental Stress in Relation to Biological Markers of Cardiovascular Health and Health Behaviors in Women","Pilot Study for Geospatial Analysis of Neighborhood Environmental Stress in Relation to Biological Markers of Cardiovascular Health and Health Behaviors in Women","* INCLUSION CRITERIA:\n\nIndividuals eligible for this protocol:\n\n1. A healthy self-identified White female (i.e. self-identifies as White or of European descent) or healthy Black female (i.e. self-identifies as Black, African American, or of African descent)\n2. Must be between 19 to 45 years of age\n3. Must not have any chronic health condition (i.e.: cardiovascular, autoimmune, endocrinologic), or active infection\n4. Must be living in Washington, DC\n5. Must have access to a smartphone\n6. Must be able to provide informed consent\n7. Must speak English.\n\nEXCLUSION CRITERIA:\n\n1. Pregnant or breast feeding\n2. Physically unable to perform physical activity for any reason\n3. Subject had weight changes greater than 20% over the past 3 months\n4. Subject is obese by our measurements (BMI greater than or equal to 35.0 kg\u002Fm\\^2)\n5. If you have high or low blood pressure requiring medications\n6. Diabetes\n7. History of severe mental illnesses, treated with hospitalization\n8. If you have evidence of active thyroid disease requiring medications\n9. If you are taking medication for chronic non-mental health related illness (ie: cardiovascular, autoimmune, endocrinologic)\n10. If you have food allergies or highly restrictive diets that may prevent your ability to consume a controlled metabolic diet.\n11. If you are a current smoker (tobacco products)","FEMALE","19 Years","45 Years",{"count":61,"type":23},250,"OBSERVATIONAL","Background:\n\nHeart disease is a leading cause of death in the United States. Healthy diet and exercise improve heart health. Some features of where a person lives can lead to stress and decrease chances for exercise. Researchers want to see how these factors may increase the risk of heart disease in women.\n\nObjective:\n\nTo see if there are differences in stress levels between women who live in different parts of Washington, DC. Also, to see how these women use their neighborhoods for exercise.\n\nEligibility:\n\nHealthy white or black females ages 19-45 who live in Washington, DC, who have access to a smartphone\n\nDesign:\n\nParticipants may stay at the NIH Clinical Center overnight for a 2-day visit.\n\nVisit 1 will include:\n\nPhysical exam\n\nBlood tests\n\nElectrocardiogram: Electrodes on the participant s skin will measure heart activity.\n\nPET\u002FCT scan: Participants will get an injection. They will lie in a machine that takes pictures of the body.\n\nSurveys\n\nBody size measurements\n\nNutrition consultation\n\nBlood vessel tests: This is measured with blood pressure cuffs, a device placed on the participant s fingertip, and a probe placed on the participant s neck.\n\nResting Energy Expenditure: Participants will breathe under a clear hood for 45 minutes.\n\nParticipants will be followed for about 2 weeks. They will wear a device on the wrist and carry a GPS device. Through a mobile app, they will answer short daily surveys on stress and exercise.\n\nVisit 2-\n\nDevice return\n\nNutritional consultation",[30],[66,67,68,69,70,71],"Neighborhood Environment","Cardiovascular Disease Risk","Social Determinants of Health","Diagnostic Behavioral study","Socio-Economic","Natural History","2026-08-14",{"date":74,"type":41},"2026-08-17",{"date":76,"type":41},"2021-10-20",{"date":78,"type":23},"2026-12-26",{"name":80,"class":81},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":91,"targetDuration":93,"studyType":62,"phases":4,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":82},"100646302","heart-and-blood-vessels-health-in-people-with-cystic-fibrosis-100646302","NCT07692594","Heart and Blood Vessels Health in People With Cystic Fibrosis","Cardiovascular Health in People With Cystic Fibrosis","CHi-CF","Inclusion Criteria:\n\n* Confirmed diagnosis of cystic fibrosis, based on sweat chloride testing and\u002For CFTR genotyping\n* Aged 18 years or older\n* Currently receiving CFTR gene modulators, defined as elexacaftor\u002F tezacaftor\u002F ivacaftor (ETI), or any next generation gene modulators after ETI, introduced for at least 3 months\n* On licensed doses that is listed on Summary of Product Characteristics of each CFTR gene modulator.\n* Clinically stable at the time of assessment (no pulmonary exacerbation or hospitalisation in the past 4 weeks)\n\nInclusion Criteria for healthy control:\n\n• Clinically stable at the time of assessment (no pulmonary exacerbation or hospitalisation in the past 4 weeks)\n\nExclusion Criteria:\n\n* On long term steroids, or any vasoactive medications\n* Diagnosed with end stage organ diseases\n* Diagnosed with rheumatoid arthritis, and\u002For systemic lupus erythematosus\n* Pregnancy or breastfeeding\n* are a smoker, or have been smoking in the last 10 years\n* Inability to undergo vascular assessments (e.g. upper limb vascular anomalies, limb injury)\n* Inability to comply with fasting instructions (for blood draws)\n* Had an organ transplantation",{"count":92,"type":23},32,"1 Year","Cystic fibrosis (CF) is a disease that affects over 11,000 people in the UK. It is a genetic condition that affects many organs including the lungs, pancreas, kidneys and liver. New drugs called \"modulators\" have meant people with CF are now living much longer. Until recently, heart disease was rare in CF, but with the new modulators there are increasing concerns that heart disease may become a big problem in the future. This is partly to do with the drugs causing weight gain and higher blood pressure, which are risk factors for heart disease.\n\nMy PhD project aims to find out whether the blood vessels and hearts of people with CF are healthy or diseased. I will then find out how the blood vessels are changing over time and work out what things are driving those changes.\n\nI will measure the health of the blood vessels and heart using an ultrasound machine to understand what the pattern of disease is like and who might be at the highest risk for heart disease in the future. I will then repeat these measurements a year later. I will compare people of different ages and with different types of disease to understand what things may help us identify heart disease as soon as possible.\n\nIn the general population, doctors often use medical prediction tools to find out who is at the highest risk for heart disease. We do not know if these work for people with CF, so I will also find out whether those prediction tools are useful in CF.\n\nIt is vital to understand who may be at risk for heart disease, as one of the most effective ways of treating heart disease is to prevent it from happening. This work may pave the way for future studies to test early treatment for heart disease in those people we identify might be at high risk. Early prevention treatment could reduce the risk of heart disease and ultimately improve the length and quality of life of people living with CF. This is particularly important given people with CF already have a much shorter life expectancy than the general population.\n\nIn summary, this PhD project will help improve our understanding of heart disease in CF and help identify the best way forward to prevent heart disease causing health problems related to heart disease for these individuals in the future.",[96,30,97,98],"Cystic Fibrosis (CF)","Flow-mediated Dilation Evaluation of the Brachial Artery","Pulse Wave Analysis",[100,101,102,103,104],"Cystic Fibrosis","Cardiovascular risk","cardiovascular diseases","Flow mediated dilation","Pulse wave analysis","NOT_YET_RECRUITING","2026-08-13",{"date":72,"type":41},{"date":109,"type":23},"2026-09-01",{"date":111,"type":23},"2028-08-30",{"name":113,"class":48},"Liverpool Heart and Chest Hospital NHS Foundation Trust",{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":57,"minAge":20,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":24,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100625770","weight-management-after-cancer-for-survivors-in-rural-communities-100625770","NCT07426952","Weight Management After Cancer for Survivors in Rural Communities","Development and Pilot Testing of a Novel Intervention to Reduce Cardiovascular Disease Risk Among Breast Cancer Survivors Living in Rural, Medically Underserved Communities","WeCan-Rural","Inclusion Criteria:\n\n* aged 18 years or older\n* female (biological sex)\n* diagnosis of stage I-III breast cancer\n* completed treatments with curative intent (with the exception of hormonal treatments) in the last 5 years\n* body mass index \\>30\n* healthy enough to participate in home-based physical activity\n* able to speak\u002Fread English\n* reports rating of ≥4 (i.e., moderate or more severe) out of 10 for one or more of the following symptoms at its worst in the last month (per the MD Anderson Symptom Inventory): pain, fatigue, sadness, and\u002For distress\n\nExclusion Criteria:\n\n* visual, hearing or cognitive impairment or severe mental illness interfering with participation",{"count":22,"type":23},[26],"This study is testing a new program called WeCan-Rural, designed to help breast cancer survivors manage symptoms and build healthy habits like eating well, staying active, and managing their weight. These changes may help lower the risk of heart disease after cancer treatment.\n\nThe study will answer two main questions:\n\n* Can study team successfully recruit and keep participants in the study, and will the participants find the program helpful and easy to follow?\n* Will participants who join the program see better results in areas like weight, symptoms, diet, physical activity, and confidence in managing the participant's health compared to those who receive standard care?\n\nHere's what participants will do:\n\n* Visit the participant's clinic twice (about 12 weeks apart) to be weighed, have the blood pressure checked, give a blood sample, and complete a short walking test\n* Fill out online surveys about the participant's health, diet, physical activity, symptoms, and confidence in managing the participant's health\n* Be randomly assigned (like flipping a coin) to either receive the WeCan-Rural program or standard health information\n* If assigned to the program, attend 12 weekly one-hour video sessions on Zoom with a trained therapist",[126,127,30,128],"Breast Cancer Survivorship","Weight Management","Breast Cancer","2026-08-11",{"date":106,"type":41},{"date":132,"type":23},"2026-08",{"date":134,"type":23},"2026-12-31",{"name":136,"class":48},"Duke University",5,{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":82},"100651488","oxidative-stress-and-cardiovascular-risk-in-patients-with-rheumatoid-arthritis-100651488","NCT07760662","Oxidative Stress and Cardiovascular Risk in Patients With Rheumatoid Arthritis","Oxidative Stress and Cardiovascular Comorbidity in Patients With Rheumatoid Arthritis","PIFIISC23\u002F07","Inclusion Criteria:\n\n* Men or women who are not pregnant or breastfeeding.\n* Age 18 years or older and younger than 70 years.\n* Treatment with any disease-modifying antirheumatic drug, including biologic therapies.\n* For patients receiving oral corticosteroids, a prednisone dose of 10 mg or less that has remained stable for at least one month before study inclusion.\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Autoimmune rheumatic disease other than RA, including systemic lupus erythematosus, mixed connective tissue disease, systemic sclerosis, or polymyositis. Sjögren syndrome associated with RA will not be an exclusion criterion.\n* Functional class IV RA with complete or substantial disability, including confinement to bed or wheelchair that prevents personal self-care.\n* History or current presence of inflammatory joint disease other than RA, such as gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, or Lyme disease.\n* Estimated glomerular filtration rate below 60 mL\u002Fmin\u002F1.73 m² or active renal disease.\n* Pregnancy or breastfeeding.\n* Evidence of severe uncontrolled concomitant cardiovascular, neurological, pulmonary (including obstructive lung disease), renal, hepatic, endocrine (including diabetes mellitus), or gastrointestinal disease, or any condition considered by the investigator likely to alter the lipid profile.\n* Body weight greater than 150 kg.\n* History of alcoholism, drug abuse, or substance misuse within six months before the screening visit.\n* Statin use will not be an exclusion criterion.",{"count":147,"type":23},200,"The pathogenic process underlying atherosclerosis resembles a chronic inflammatory response in which oxidative stress is involved. Similarly, oxidative stress is widely recognized to play an important role in the clinical course and pathogenesis of rheumatoid arthritis (RA). RA has been associated with accelerated atherosclerosis.\n\nThis cross-sectional study will include patients with RA. The primary objective is to evaluate the association between selected oxidative stress biomarkers-serum malondialdehyde levels, superoxide dismutase, and glutathione peroxidase-and the presence of subclinical atherosclerosis and carotid arterial stiffness in patients with RA. We will subsequently assess whether these molecules are related to cardiovascular disease determinants, including inflammatory dyslipidemia, insulin resistance, and beta-cell dysfunction, which may occur in this condition. This study will further explore the relationship between oxidative stress and cardiovascular disease in RA.",[150,151,30],"Rheumatoid Arthritis (RA","Oxidative Stress",[153,154],"Rheumatoid arthritis","Oxidative stress","2026-08-07",{"date":157,"type":41},"2026-08-12",{"date":159,"type":41},"2024-01-01",{"date":161,"type":23},"2026-12",{"name":163,"class":48},"University of La Laguna",{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":18,"sex":19,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":191},"100649872","work-related-frustration-and-higher-cardiovascular-risk-blood-pressure-profiles-100649872","NCT07740434","Work-Related Frustration and Higher Cardiovascular Risk Blood Pressure Profiles","Work-Related Frustration and Higher Cardiovascular Risk Blood Pressure Profiles: A Regional Proof-of-Concept Study on Work-Related Quality of Life and Cardiovascular Prevention.","TRACA","Inclusion Criteria:\n\n* Patients aged 40 to 65 years\n* Consulting one of the participating general practitioners,\n* Actively working\n* Without cardiovascular history or antihypertensive treatment","40 Years","65 Years",{"count":175,"type":23},316,"Background: Mental health is a national priority in France, especially in the workplace. The impact of poor quality of life at work on mental health has been demonstrated. Raising awareness of the importance of prevention within companies and the influence of working conditions seems essential. In the context of limited occupational health physicians, inherent access difficulties, and reduced resources, physical health is often addressed as the first line of intervention. In the Burgundy region, the prevention of cardiovascular diseases is a regional public health concern. A significant association has been found between effort\u002Freward imbalance and masked hypertension. Identifying a link between working conditions, blood pressure profile, and thus increased cardiovascular risk would be relevant.\n\nObjectives: The main goal of this observational study is to compare the frequency of blood pressure profiles at higher risk of cardiovascular events (white coat hypertension and daytime and\u002For nighttime masked hypertension) according to work-related quality of life and perceived stress levels among primary care patients without a history of hypertension or cardiovascular disease, in two departments of the Burgundy region.\n\nMethods: This project is a proof-of-concept study before intervention on work-related quality of life and blood pressure profiles at higher cardiovascular risk in primary prevention. It is a prospective, interventional, and multicenter study, conducted from May 2023, across three multidisciplinary primary care centers, involving fifteen general practitioners from Côte d'Or and Saône-et-Loire. Patients aged 40 to 65, consulting one of the participating general practitioners, actively working, with no cardiovascular history or antihypertensive treatment, will be included. Work-related quality of life and perceived stress will be assessed using the QualTra-Scale and the PSS-10 scale, respectively. All included patients will undergo 24-hour ambulatory blood pressure monitoring (ABPM) during a workday. A qualitative component will complement the results through patients' individual interviews exploring ABPM perception and reasons for refusal, and focus groups involving general practitioners and occupational health professionals to explore perceptions and potential intervention strategies.\n\nPerspectives: The main perspective of this study is to focus on workplace health by providing additional data on the physical repercussions of poor work-related quality of life and high perceived stress. Objectifying a confirmed medical situation could serve as a lever for identifying mental health issues. It would enable interventions to improve work-related quality of life by addressing health determinants and psychosocial risks. Various interventions could be considered through a multidisciplinary approach in the workplace, involving occupational physicians, occupational psychologists, and employers. This study could also offer insights into patient profiles at higher cardiovascular risk, help develop recommendations for screening masked hypertension, and evaluate the role of blood pressure measurements at the workplace.",[178,30,179,180,181],"Blood Pressure Monitoring, Ambulatory","Quality of Life at Work","Hypertension","Frustration","2026-07-28",{"date":184,"type":41},"2026-07-31",{"date":186,"type":41},"2023-05-22",{"date":188,"type":23},"2028-05",{"name":190,"class":48},"University of Burgundy",3,{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":18,"sex":57,"minAge":199,"maxAge":173,"enrollmentInfo":200,"targetDuration":4,"studyType":24,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":4},"100645722","female-specific-modifiers-for-healthy-early-action-in-cardiovascular-risk-trajectories-100645722","NCT07703124","Female-Specific Modifiers for Healthy Early Action in Cardiovascular Risk Trajectories","FEM-HEART","Inclusion Criteria:\n\n* women aged \\>35 years in the perimenopausal transition\n* women within 5 years after menopause and and younger than 65 years\n* women with two of the following: (i) established cardiovascular risk factors, such as hypertension, dyslipidemia, overweight, or smoking; (ii) female-specific and hormone-related factors, such as pregnancy-associated complications or early menarche; and (iii) elevated psychosocial stress, assessed by validated questionnaires and physiological proxies.\n\nExclusion Criteria:\n\n* high levels of physical activity\n* hormone replacement therapy\n* major comorbidities such as diabetes, moderate-to-severe kidney or liver disease, malignant tumors, musculoskeletal or neurological conditions limiting mobility, congenital heart defects, prior cardiac events, or a history of thrombosis.","35 Years",{"count":201,"type":23},605,[26],"Cardiovascular disease is the leading cause of death in women, yet risk is systematically underestimated and preventive interventions are often initiated too late. Women are disproportionately affected by obesity, diabetes, and smoking, but they also derive greater cardioprotective benefit from physical activity, reaching near-maximal protection at approximately half the exercise dose required in men. FEM-HEART targets a critical pre-clinical window by testing whether a personalized app-based intervention and a supervised face-to-face lifestyle program, both integrating tailored exercise, nutrition, and stress reduction, can improve early cardiovascular risk profiles in high-risk women during the peri- and postmenopausal transition.\n\nIn this prospective randomized controlled trial embedded in routine preventive care at SVS Gesundheitszentrum, 605 women will be randomized to a digital arm, a supervised intervention arm, or an untreated control group. The study will evaluate whether digital and supervised delivery formats differ in their ability to modify early cardiovascular trajectories before overt disease onset.\n\nBy targeting this modifiable pre-clinical phase, FEM-HEART shifts cardiovascular prevention from reactive care to proactive, sex-specific risk reduction and lays the foundation for scalable, woman-centered prevention strategies.",[205,206,30],"Perimenopausal Women","Postmenopausal Female Patients","2026-07-19",{"date":209,"type":41},"2026-07-21",{"date":211,"type":23},"2027-06-01",{"date":213,"type":23},"2031-10-31",{"name":215,"class":48},"Ludwig Boltzmann Institute for Cardiovascular Research",{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":19,"minAge":199,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":24,"phases":226,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":137},"100645551","multicenter-cardiac-decision-impact-study-in-people-with-breast-cancer-100645551","NCT07703033","Multicenter Cardiac Decision Impact Study in People With Breast Cancer","ARTILLERY-CarDI, Early Detection of Non-communicable Disease Risk in People With Breast Cancer: Multicenter Cardiac Decision Impact Study","CarDI","Inclusion Criteria:\n\n* diagnosed with breast cancer or ductal carcinoma in situ\n* Planned for radiotherapy\n* From 35 years of age onwards\n\nExclusion Criteria:\n\n* Pregnancy\n* Breastfeeding",{"count":225,"type":23},1000,[26],"Background:\n\nBreast cancer is the most common cancer in women, and advances in early detection and treatment have led to steadily improved survival rates. Today, nearly 80% of breast cancer survivors are over 50 years of age. With longer survival, comes a greater burden of chronic disease, particularly cardiovascular disease (CVD), which is more common in breast cancer survivors than in the general population. This elevated risk is driven by treatment-related effects, such as chemotherapy- and radiotherapy-induced cardiotoxicity, metabolic changes including (therapy-associated) weight gain, and shared lifestyle risk factors such as obesity and physical inactivity. In routine clinical care, approximately 65% of breast cancer patients undergo local radiotherapy (RT) and will receive a planning computed tomography (CT) scan. These scans, while intended for RT planning, also capture valuable information on coronary artery calcifications (CAC), a well-established marker risk factor of CVD risk.\n\nThe ARTILLERY-CarDI study is a multinational decision impact trial which will evaluate calculating CAC-based CVD risk (Agatston score) and communicating personalized, risk-based management recommendations to breast cancer patients.\n\nAims and outcomes:\n\nIn this study, CVD risk is estimated based on the manual CAC (Agatston) score using RT planning CT scans and a corresponding CVD risk-based recommendation is provided to breast cancer patients. The main aim of this study is to disclose this estimated CVD risk to treating physicians and patients and investigate how this risk affects:\n\n1. breast cancer treatment (retrospectively) and cardiovascular care (i.e., no further action, recommendation for lifestyle changes, referral to a cardiologist or general practitioner (GP)), and\n2. patients' satisfaction with their decision to receive their estimated CVD risk and the corresponding CVD risk-based management.\n\nSecondary aims are to evaluate whether the knowledge of estimated CVD risk and corresponding CVD-risk based management impacts patients' decisions regarding their lifestyle and habits, decisional conflict regarding lifestyle decision changes, patient reported outcomes (PROs) and changes in CVD risk factors and CVD treatment.\n\nMethods:\n\nARTILLERY-CarDI is a multinational, multicenter, prospective decision impact trial, designed as a within-subject trial in which participants serve as their own controls. A total of 1,000 patients with breast cancer will be enrolled over 1.5 years across five centers in four countries (the Netherlands with two participating centers, Germany, Portugal, and Denmark). Each participant will be followed for six months.\n\nThe intervention is the CVD risk estimation based on the CAC (Agatston) score using RT planning CT scans, and the subsequent disclosure of the estimated CVD risk and corresponding CVD risk-based management to the patient using the ARTILLERY manual. The CAC (Agatston) score will be measured after the RT planning CT scan is made, which is usually one or two weeks before the start of RT. The Agatston score is a validated method for CVD risk assessment using the amount of CAC. CVD risk is categorized in 5 groups with an Agatston score of 0, 1-10, 11-100, 101-400, and \\>400. In the current trial, endpoints will be analyzed according to low, moderate, and high-CVD-risk groups corresponding to score ranges 0-10, 11-100, and \\>100, respectively.\n\nFollowing a study-specific manual , eligible patients will be referred to a cardiologist or GP if a previously unknown moderate to high risk of CVD according to CAC is determined (Agatston score \\>10). Thereafter, these patients will be treated accordingly as part of standard care. We expect that the timely measurement of estimated CVD risk by the amount of CAC on a planning CT scan and the disclosure of CVD risk-based management is beneficial for patients. The CVD risk measurement will lead to the identification of breast cancer patients with a previously unknown moderate to high estimated CVD risk and possibly undertreated cardiac conditions. The disclosure of CVD risk-based management is intended to empower patients to manage their own physical health and well-being. Also, we expect that the CVD risk measurement and CVD risk-based management will create more awareness among doctors and citizens about CVD risk in breast cancer patients. A potential side-effect of CAC- based CVD risk measurement and disclosure of CVD risk-based management is that, some patients may experience increased anxiety leading to dissatisfaction or regret about their decision to participate. The Satisfaction with Decision (SWD) questionnaire will be used to measure patients' satisfaction about their decision as one of the primary outcomes and the level of anxiety by the Hospital Anxiety and Depression Scale, at baseline, at one month and at six months after the intervention.",[128,30,229],"Coronary Artery Calcifications",[231,232,233,234,235],"Radiotherapy planning CT scans","Decision impact trial","patient reported outcomes","decisional conflict","satisfaction with decision","2026-07-08",{"date":238,"type":41},"2026-07-14",{"date":240,"type":41},"2026-04-20",{"date":242,"type":23},"2028-05-01",{"name":244,"class":48},"UMC Utrecht",{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":18,"sex":57,"minAge":172,"maxAge":253,"enrollmentInfo":254,"targetDuration":256,"studyType":62,"phases":4,"briefSummary":257,"conditions":258,"keywords":264,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":277},"100646115","caramel-observational-study-100646115","NCT07695376","CARAMEL Observational Study","CArdiovascular Risk Assessment Via Multimodal Data Analysis Enabling Personalised Prevention Strategies Targeting MEnopausaL Women - Observational Study","CARAMEL-OS","Inclusion Criteria:\n\n* Women 40 to 60 years of age, at recruitment.\n* Ability to understand and complete the required informed consent for the study.\n* Women who are covered by the corresponding healthcare system operating at each clinical site.\n\nExclusion Criteria:\n\n* Severe comorbidity with less than 24 months life expectancy.\n* Lack of basic digital skills to use or carry a smartphone and wearable devices.","60 Years",{"count":255,"type":23},3000,"24 Months","CARAMEL is a project funded by the European Commission under the Horizon Europe programme. Its aim is to develop a personalized prevention approach based on state-of-the-art artificial intelligence models for cardiovascular risk stratification in women aged 40-60 years. These models are trained using large amounts of multi-source data and complemented by digital self-assessment and self-management tools. The CARAMEL consortium brings together a diverse group of 25 organizations, including technology companies and research centers, clinical institutions, as well as experts in ethics, law, and communication.\n\nThe CARAMEL-OS study is an observational study aimed at prospectively completing the proposed personalized cardiovascular risk stratification model for women aged 40-60 years that will be developed during the earlier phases of the overall CARAMEL project (https:\u002F\u002Fwww.caramel-project.eu\u002F).\n\nThe study has a purely observational design, and patient stratification will not entail any clinical intervention. The data collected will be used to complete the design of the personalized stratification model, as well as to develop and validate the performance of the predictive models in an independent prospective cohort, distinct from the retrospective cohort initially used. The performance of the models developed using retrospective data will be assessed in terms of accuracy, discrimination, calibration, and other relevant metrics. In addition, the study will enable the development of new predictive models with short-term prediction horizons, incorporating additional variables that are not available retrospectively.\n\nThe study population will be recruited in four European Union countries: Croatia, Spain (Andalusia and The Basque Country - Gipuzkoa), Greece and Lithuania; and in Colombia. A prospective cohort of 3,000 women aged 40-60 will be recruited, with each partner contributing 500 participants.",[259,260,30,261,262,263],"Perimenopause","Menopause","Women (Between 30 to 60 Years Old)","Cardiovascular Disease Risk Factor","Artificial Intelligence (Al)",[265,30,259,260,266,267],"Women-specific risk factors","Prediction models","Patient reported outcomes (PROM)","2026-07-06",{"date":270,"type":41},"2026-07-10",{"date":272,"type":41},"2026-03-16",{"date":274,"type":23},"2028-11",{"name":276,"class":48},"Biogipuzkoa Health Research Institute",6,{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":24,"phases":288,"briefSummary":289,"conditions":290,"keywords":295,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":303,"leadSponsor":305,"locationsCount":82},"100646696","growing-healthy-hearts-100646696","NCT07684027","Growing Healthy Hearts","Growing Healthy Hearts: A Randomized Controlled Trial of a Multicomponent Gardening Intervention for Adults With Cardiovascular Disease Risk and Their Families.","GHH","Inclusion Criteria:\n\n* Adults aged 18 or older who are interested in gardening but have no plans to garden in the coming season.\n* Participants will also be required to: 1) have at least one child (aged 5-17) living in the household with them\n* Have access to space for a garden (either at home or in a community garden space where they could plant any combination of in-ground, raised beds, and\u002For container gardens\n* Have a smartphone capable of downloading an app and syncing with a Fitbit\n* Access to the internet\n* Have or are willing to create a Facebook account\n* Report ≤90 minutes of moderate or vigorous physical activity \u002Fweek\n* Report \\\u003C5 servings of fruit and vegetables per day\n* Have any one additional self-reported CVD risk factor (e.g., BMI ≥25, family history of premature CVD, high blood pressure, high cholesterol, diabetes, current or past tobacco use)\n\nExclusion Criteria:\n\n* Adults who are pregnant\n* Have medical conditions that significantly limit an individual's ability to participate in gardening (e.g., knee or back pain, heart attack\u002Fstroke in the past year, recent or pending surgeries\n* Uncontrolled allergies, other serious physical disabilities, uncontrolled asthma)\n* Medical conditions that may limit participants from increasing FV intake (e.g., kidney failure or dialysis)",{"count":287,"type":23},264,[26],"This proposal includes a prospective, parallel group, two-arm RCT with 264 adult-child dyads (adult age 18+, child ages 5-17 years) to examine the effectiveness of the Growing Healthy Hearts (GHH) intervention versus a wait list control on cardiovascular and behavioral health outcomes at 3-, 6- and 12-months follow-up (Aim 1). This proposal will also examine the effect of GHH on home fruit and vegetable (FV) availability, frequency of home-prepared meals that include FV, and child behaviors (FV intake and PA) at 3-, 6- and 12-month follow-up (Aim 2) and intervention implementation (Aim 3)",[30,291,292,293,294],"Behavioral Changes","Gardening","Cooking","Nutrition Education",[296,297,298],"self-determination theory","CVD risk factors","diet quality","2026-07-02",{"date":301,"type":41},"2026-07-07",{"date":45,"type":23},{"date":304,"type":23},"2031-03",{"name":306,"class":48},"Milton S. Hershey Medical Center",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":314,"targetDuration":93,"studyType":62,"phases":4,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":82},"100625819","prospective-evaluation-of-new-metrics-to-assess-cardiovascular-remodeling-in-obstructive-sleep-apnea-100625819","NCT07427589","Prospective Evaluation of New Metrics to Assess Cardiovascular Remodeling in Obstructive Sleep Apnea","CARDOSA","Inclusion Criteria:\n\n* AHI ≥ 15 events\u002Fhour, based on a recent (\\\u003C2 years) PSG, conducted in Antwerp University Hospital\n* Patients must be 18 years or older\n* Patients must be dutch-speaking\n* Patients must be eligible for their therapy (CPAP, MAD or HNS)\n* Willing to participate after informed consent\n\nExclusion Criteria:\n\n* Central apneas accounting for ≥25% of total apneas during baseline polysomnography\n* Patients who have received effective CPAP therapy (defined as CPAP use for ≥4 h\u002Fnight) within the previous 6 months\n* Patients with prior MAD therapy\n* Uncontrolled hypertension\n* Known cardiomyopathy\n* Significant coronary arterial disease\n* Clinically significant valvular heart disease, defined as more than mild left-sided valvular disease or more than moderate right-sided valvular disease\n* Congenital heart disease\n* Participants may be excluded if, after rescoring, outcome measures do not meet predefined criteria",{"count":315,"type":23},270,"The goal of this prospective study is to gain insight into the endophenotypic variation in OSA, with a focus on the underlying pathophysiological traits and the cardiovascular alterations associated with the condition. To capture the variability in OSA endophenotypes, novel metrics that extend beyond the AHI will be considered, with particular attention to the sleep-apnea-specific hypoxic burden, the sleep-apnea-specific heart rate response, and pulse wave amplitude drops (PWADs). Since the impact of treatment on cardiovascular parameters remains an important point of interest, the effects of different treatment modalities on cardiovascular changes will be investigated, including continuous positive airway pressure (CPAP), mandibular advancement devices (MADs), and hypoglossal nerve stimulation.",[318,30],"Obstructive Sleep Apnea","2026-06-24",{"date":321,"type":41},"2026-06-29",{"date":323,"type":41},"2026-06-10",{"date":325,"type":23},"2029-12",{"name":327,"class":48},"University Hospital, Antwerp",{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":19,"minAge":335,"maxAge":336,"enrollmentInfo":337,"targetDuration":4,"studyType":24,"phases":339,"briefSummary":340,"conditions":341,"keywords":345,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":4},"100644755","a-two-part-intervention-to-target-cardiovascular-health-100644755","NCT07673172","A Two-Part Intervention to Target Cardiovascular Health","Autism Research Consortium on Physical Health: A Two-Part Intervention to Target Cardiovascular Health","Inclusion Criteria:\n\n* • Have a diagnosis of autism or be told by a healthcare provider that you have autism\n\n  * Be between the ages of 9 and 26\n  * Have a BMI greater than the 84th percentile\n  * English speaking\n\nExclusion Criteria:\n\n* • Children younger than 9 years of age\n\n  * Adults older than 26 years of age\n  * Individuals without a diagnosis of autism\n  * Individuals with a BMI less than the 84th percentile","9 Years","26 Years",{"count":338,"type":23},130,[26],"Obesity is one of the most common health conditions among autistic young people and its prevalence rises at faster rates for autistic-relative to non-autistic-individuals. This places them at heightened risk for cardiovascular disease (CVD) and mortality before they enter adulthood. Studies have identified three key contributing factors to CVD outcomes in autistic individuals: unhealthy lifestyle behaviors, Adverse Childhood Experiences (ACEs), and chronic stress.\n\nThis study will explore the effectiveness of two CVD-focused primary care interventions for autistic individuals (ages 9-26): (1) lifestyle medicine consultations tailored towards supporting health-promoting behaviors; and (2) a Cognitive Behavioral Therapy (CBT) intervention tailored towards addressing chronic stress that contributes to excess weight and maladaptive eating behaviors and results in obesity and CVD. Participants and their caregivers will be randomly placed into either the Lifestyle Medicine Group, CBT Group, or combined Lifestyle Medicine with CBT Group. Participants will respond to questionnaires and surveys measuring lifestyle habits, stress, and psychological risk factors at their first visit, 6-month visit, and 3 months post-intervention visit. Over the course of 6 months, participants will attend virtual sessions (up to three times a month) in accordance with their intervention group.",[342,343,344,30],"Autism","Adverse Childhood Experience","Stress",[346,347,348,349],"autism","adverse childhood experiences","stress","cardiovascular risk","2026-06-22",{"date":321,"type":41},{"date":353,"type":23},"2026-07-01",{"date":355,"type":23},"2028-08-31",{"name":357,"class":48},"University of California, Los Angeles",{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":18,"sex":19,"minAge":172,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":24,"phases":367,"briefSummary":368,"conditions":369,"keywords":370,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":4},"100637757","democratizing-access-to-cleaner-residential-air-100637757","NCT07629518","Democratizing Access to Cleaner Residential Air","DACRA","Inclusion Criteria:\n\nAge 40 years or older Speaks English, Vietnamese, and\u002For Chinese Cognitive capacity to respond to questionnaires Lives fulltime at the current address, adjacent (\\\u003C 200 meters) to roadways with large traffic volumes Must have one or more risk factors (hypertension or elevated blood pressure, pre-diabetes or diabetes or elevated blood sugar levels, elevated cholesterol levels, body mass index 25 or greater)\n\nExclusion Criteria:\n\nPregnant Works between the hours of 10 PM and 6 AM Sources of smoke in the living space (such as candles, incense, marijuana, wood stove, fireplace) almost every day\u002Fevery day.\n\nEvery day exposure to motor vehicle exhaust (from cars, trucks, buses, trains), including heavy street or highway traffic.\n\nCurrently smoking or vaping Others smoking or vaping indoors, in the living space. Within the past 5 years, a diagnosis of heart attack, heart disease, stroke, blood clots or pulmonary embolism, cancer requiring surgery and\u002For chemo\u002Fradiation therapy",{"count":366,"type":23},66,[26],"The purpose of this research study is to determine whether the use of in-home air filtration to reduce exposure to air pollution benefits health.",[30],[371,372,373,349,374],"air pollution","air purifiers","HEPA filtration","biomarkers","2026-06-01",{"date":377,"type":41},"2026-06-05",{"date":379,"type":23},"2026-09",{"date":381,"type":23},"2029-05",{"name":383,"class":48},"Douglas Brugge",{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":19,"minAge":172,"maxAge":391,"enrollmentInfo":392,"targetDuration":4,"studyType":24,"phases":394,"briefSummary":395,"conditions":396,"keywords":397,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":82},"100638150","cardiovascular-prevention-supported-by-digital-technology-comparison-with-the-traditional-model-100638150","NCT07608926","Cardiovascular Prevention Supported by Digital Technology: Comparison With the Traditional Model","DIGITAL PREV","Inclusion Criteria:\n\n* Age between 40 and 75 years\n* hypertension\n* hyperglycaemia\n* type 2 diabetes not requiring insulin therapy\n* dyslipidaemia\n* active smoking\n* overweight\u002Fgrade I obesity\n* Willingness to participate in follow-up visits over 24 months\n\nExclusion Criteria:\n\n* previous myocardial infarction\n* stroke\n* transient ischemic attack\n* coronary artery diseas\n* peripheral arterial occlusive disease\n* heart failure\n* Type 1 or type 2 diabetes mellitus on insulin therapy\n* Advanced chronic kidney disease (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n* Active cancer disease\n* Severe obesity\n* Inability to use digital tools\n* Pregnancy","75 Years",{"count":393,"type":23},144,[26],"Cardiovascular diseases represent one of the leading causes of morbidity and mortality worldwide. Prevention in patients at cardiovascular risk is essential to reduce the incidence of cardiovascular events and slow the progression of risk.\n\nThis study aims to evaluate the effectiveness and feasibility of a cardiovascular prevention pathway delivered remotely through a digital application, comparing it with a traditional in-person care pathway.",[30],[398,399],"Cardiovascular risk factors","Prevention","2026-05-19",{"date":402,"type":41},"2026-05-27",{"date":404,"type":41},"2025-05-28",{"date":406,"type":23},"2028-06",{"name":408,"class":48},"Maria Cecilia Hospital",{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":18,"sex":19,"minAge":416,"maxAge":417,"enrollmentInfo":418,"targetDuration":4,"studyType":24,"phases":420,"briefSummary":421,"conditions":422,"keywords":423,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":435,"locationsCount":4},"100638762","cardiometabolic-effects-of-low-fat-and-full-fat-dairy-100638762","NCT07605442","Cardiometabolic Effects of Low-Fat and Full-Fat Dairy","Cardiometabolic Effects of Low-Fat and Full-Fat Dairy in Healthy and Cardiometabolically At-Risk Adults","Inclusion Criteria:\n\n* BMI 18.5 to 39.9 kg\u002Fm2\n* LDL-C ≤190 mg\u002FdL assessed by the Modified Sampson-NIH Equation\n* Currently consume milk, yogurt, and\u002For cheese daily\n* Willing to eat 3 servings of dairy (milk, yogurt, cheese) for two 6-week periods during the study\n\nExclusion Criteria:\n\n* Hemoglobin \\\u003C13.2 g\u002FdL for men or \\\u003C 11.7 g\u002FdL for women at screening\n* Fasting triglycerides \\>350 mg\u002FdL at screening\n* ≥10% change in body weight within the 6 months prior to enrollment\n* Blood pressure \\>140\u002F90 mmHg at screening\n* Fasting glucose ≥126 mg\u002FdL\n* Type 1 or type 2 diabetes\n* Takes any (prescription or over-the-counter) anti-hypertensive, lipid-lowering, glucose-lowering or anti-inflammatory drugs, or drugs that alter body weight\n* Intake of supplements that affect the outcomes of interest (i.e., lipids, blood pressure, glucose, body weight, inflammation and microbiome) and are unwilling to cease during the study period.\n* Unwilling to refrain from starting to take any supplements, vitamins, nutritional products, or health foods that are not prescribed by a doctor for the duration of the study\n* History of liver, kidney, or autoimmune disease\n* Prior cardiovascular event (e.g., stroke, heart attack)\n* Current pregnancy or intention of pregnancy within the next 12 months\n* Lactation within the prior 6 months\n* Dairy allergy\u002Fintolerance\u002Fsensitivity\u002Fdislike\n* Antibiotic use within the prior four weeks\n* Oral steroid use within the prior four weeks\n* Use of tobacco or nicotine-containing products within the past 6 months\n* History of cancer at any site within the past 10 years (eligible if ≥10 years without recurrence) or non-melanoma skin cancer within the past 5 years (eligible if ≥5 years without recurrence)\n* Participation in another clinical trial within 60 days of baseline\n* Currently following a restricted or weight-loss diet\n* Prior bariatric surgery\n* Intake of \\>14 alcoholic drinks\u002Fweek and\u002For not willing to avoid alcohol consumption for 48 hours prior to test visits\n* Does not speak and\u002For understand English\n* Unwilling to refrain from donating blood and\u002For plasma during the study\n* Weight \\\u003C110 lb\n* Lactose intolerance or sensitivity\n* Unwilling to contact study staff before enrolling in other health-related research and avoid participating in any research that may interfere with this study\n* For individuals taking thyroid medication: abnormal thyroid stimulated hormone (TSH) concentration, or change in dose of thyroid medication within the last 6 months\n* Principal Investigator discretion related to the potential participant's ability to adhere to the study requirements, including being able to come to attend visits","25 Years","70 Years",{"count":419,"type":23},178,[26],"The purpose of this study is to find out if full-fat dairy and low-fat dairy have similar effects on risk factors for heart disease and diabetes. During the study, participants will consume two types of dairy products: low-fat dairy (milk, yogurt, and cheese) and full-fat dairy (milk, yogurt, and cheese). Each type of dairy will be consumed for 6 weeks with a ≥4-week break between. Measures will be taken to evaluate blood cholesterol, blood sugar, body weight, inflammation, blood pressure, heart health and dietary intake at the beginning and end of each 6 week period.",[30],[424,425,426,427,428],"dairy","diet","nutrition","LDL-cholesterol","cardiovascular disease","2026-05-18",{"date":431,"type":41},"2026-05-26",{"date":433,"type":23},"2026-09-08",{"date":355,"type":23},{"name":436,"class":48},"Penn State University",{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":19,"minAge":59,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":24,"phases":447,"briefSummary":449,"conditions":450,"keywords":456,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":82},"100605891","phase-4-landiolol-to-avoid-tachycardia-in-patients-at-risk-for-cardiovascular-events-undergoing-major-non-cardiac-surgery-100605891","NCT07168421","LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery","LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery: a Feasibility Trial","LANTA-P","Inclusion Criteria:\n\n* Patients undergoing elective non-cardiac surgery defined as intermediate or high-risk by the 2022 european society of cardiology (ESC) guidelines\n* surgery performed under general anesthesia;\n* expected length of hospital stay ≥ 24 hours;\n* age ≥ 45 years;\n* at least two of the following risk factors:\n\n  * age ≥ 75 years\n  * arterial hypertension;\n  * ischemic heart disease (history of myocardial infarction or positive exercise test, current complaint of chest pain considered to be secondary to myocardial ischemia, use of nitrates, pathological Q waves, prior coronary revascularization);\n  * history of congestive heart failure;\n  * history of cerebrovascular disease;\n  * peripheral artery disease;\n  * diabetes mellitus;\n  * GFR ≤ 59 ml\u002Fmin pro 1.73 m2;\n  * pre-operative NTproBNP \\> 200 pg\u002Fml;\n* excessive sympathetic outflow as proven by exercise testing:\n\n  * impaired heart rate recovery (≤ 12 bpm within 1 minute after cessation of exercise); OR\n  * exaggerated heart rate response (≥ 12 bpm after 3 minutes of unloaded pedalling);\n\nExclusion Criteria:\n\n* unable to consent or follow study procedures;\n* absolute contraindications for exercise testing;\n* pregnancy or intention to become pregnant;\n* active cardiac conditions (such as unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease);\n* urgent \u002F emergency surgery;\n* already on β-blocker (within the last 30 days prior to recruitment);\n* contraindication for β-blocker therapy (bradycardia (HR \\\u003C 55 bpm), hypotension (systolic blood pressure \\\u003C 100 mmHg), severe peripheral vascular disease, severe asthma, allergy, higher-degree atrioventricular block);\n* severe preoperative anaemia (haemoglobin \\\u003C 100 g\u002FL) unless there is a plan set up and followed for correction prior to surgery;\n* planned intermediate care or intensive care admission;\n* prior enrolment in this trial.",{"count":446,"type":23},114,[448],"PHASE4","Limiting perioperative tachycardia (aiming for a heart rate \\\u003C90 beats per minute throughout the perioperative period) using the ultra-short acting beta-blocker landiolol in patients with cardiovascular risk factors undergoing major surgery might lower the incidence of perioperative myocardial injury. Feasibility of the intervention needs to be proven prior to conduction of a larger trial.",[451,452,30,453,454,455],"Perioperative Myocardial Injury","Autonomic Dysfunction","Major Surgery","Beta Blocker","Myocardial Injury After Non-cardiac Surgery",[457,458,459,460,461],"perioperative myocardial injury","major surgery","beta blocker","myocardial injury after non-cardiac surgery","autonomic dysfunction","2026-05-04",{"date":464,"type":41},"2026-05-05",{"date":466,"type":41},"2026-04-24",{"date":468,"type":23},"2028-03-01",{"name":470,"class":48},"Insel Gruppe AG, University Hospital Bern",{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":57,"minAge":20,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":82},"100614783","the-synergistic-effects-of-menopause-and-hiv-on-cardiovascular-disease-risk-in-women-100614783","NCT07284082","The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women","Inclusion Criteria:\n\n* 90 non-pregnant women with HIV (approximately 30 in each menopausal phase) from the San Francisco MWCCS site.\n\nExclusion Criteria:\n\n* Women who are not virally suppressed (HIV RNA \\>200 copies\u002FmL)\n* Women who are not on antiretroviral therapy\n* Women who have a history of hysterectomy or oophorectomy\n* Women who are receiving treatment for active cancer or tuberculosis",{"count":478,"type":23},90,"Menopause is associated with the acceleration of many comorbidities, including cardiovascular disease. Whether HIV and menopause together increase cardiovascular disease risk is a key knowledge gap. The goal of this observational study is to address this knowledge gap by looking at the role of menopause on cardiovascular disease risk factors such as insulin resistance, hypertension, hyperlipidemia, and carotid atherosclerosis using previously collected data. The investigators will look at underlying causes for cardiovascular diseases worsening in menopausal women with HIV by looking at the role of increased inflammation in the body and whether this is altered by weight. The investigators achieve this by enrolling participants who are willing to undergo a whole body MRI.",[481,260,30,482,483],"HIV","Carotid Arteriosclerosis","Body Composition",{"date":485,"type":41},"2026-04-22",{"date":487,"type":41},"2026-04-17",{"date":489,"type":23},"2030-03-01",{"name":491,"class":48},"University of California, San Francisco",{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":391,"enrollmentInfo":500,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":502,"conditions":503,"keywords":506,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":514,"leadSponsor":516,"locationsCount":82},"100634873","integrated-ultrasound-derived-fat-fraction-and-2d4d-heartai-for-cardiovascular-risk-management-in-patients-with-masld-100634873","NCT07545343","Integrated Ultrasound-Derived Fat Fraction and 2D\u002F4D HeartAI for Cardiovascular Risk Management in Patients With MASLD","Integration of Ultrasound-Derived Fat Fraction With 2D and 4D HeartAI for Cardiovascular Risk Management in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Observational Cohort Study","MUCHAI","Inclusion Criteria:\n\n* Adults aged 18 to 75 years\n* Diagnosis of MASLD based on imaging or biopsy\n* Presence of at least one cardiometabolic risk factor, such as BMI ≥25 kg\u002Fm², type 2 diabetes mellitus, or dyslipidemia\n* No contraindication to ultrasound imaging\n\nExclusion Criteria:\n\n* Significant alcohol consumption: \\>20 g\u002Fday for women or \\>30 g\u002Fday for men Secondary causes of hepatic steatosis, such as viral hepatitis or autoimmune liver disease\n* Known advanced heart failure (New York Heart Association class III-IV)\n* Recent cardiovascular event within 6 months\n* Pregnancy\n* Inability to complete follow-up",{"count":501,"type":23},700,"This prospective observational cohort study aims to evaluate the association between liver fat fraction measured by ultrasound-derived fat fraction (UDFF) and cardiac functional parameters assessed by 2D and 4D HeartAI in adult patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Participants will undergo baseline assessment and repeat evaluations at 6, 12, and 36 months. The study will assess the diagnostic performance of integrated UDFF-HeartAI analysis for detecting subclinical cardiac abnormalities and identify predictors of cardiovascular risk progression and major adverse cardiovascular events in patients with MASLD.",[504,30,505],"MASLD","Subclinical Cardiovascular Impairments",[507,508,509,510],"Ultrasound-Derived Fat Fraction","Echocardiography","Cardiovascular Events","Major Adverse Cardiovascular Events","2026-04-16",{"date":485,"type":41},{"date":375,"type":23},{"date":515,"type":23},"2030-05-31",{"name":517,"class":48},"First Affiliated Hospital, Sun Yat-Sen University",{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":18,"sex":19,"minAge":524,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":24,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":82},"100604274","lions-hearts-a-community-approach-to-multigenerational-cardiovascular-disease-risk-100604274","NCT07147387","Lions Hearts: A Community Approach to Multigenerational Cardiovascular Disease Risk","Inclusion Criteria:\n\n* Mother-child dyad willing to participate together in the full 12-week intervention and assessment activities\n* Child aged 10-17 years old\n* Mother (or female caregiver)\n* Both mother and child must be able to safely engage in moderate-to-vigorous physical activity, as determined by pre-participation health screening (e.g., PAR-Q+)\n* Access to transportation to attend twice-weekly exercise sessions at a local CrossFit affiliate\n\nExclusion Criteria:\n\n* Presence of a medical condition that would make participation in moderate-to-vigorous physical activity unsafe, as determined by health screening or medical provider (e.g., uncontrolled hypertension, cardiovascular disease, severe orthopedic limitations)","10 Years",{"count":526,"type":23},100,[26],"This pilot study evaluates the feasibility, acceptability, and preliminary effectiveness of Lion Hearts, a community-based, family-centered physical activity intervention designed to improve cardiovascular health among mother-child dyads. Developed through community co-design, the 12-week intervention is delivered in local CrossFit affiliates and includes twice-weekly fitness sessions incorporating functional movement, goal setting, teamwork, and health education. The study aims to assess changes in physical activity, fitness, and cardiovascular health markers, as well as family dynamics and motivation for physical activity. Participants complete baseline, mid-, post-, and 3-month follow-up assessments, including surveys, fitness testing, accelerometry, and optional lab work. Findings will inform the refinement of the intervention for future large-scale trials.",[30],"2026-04-01",{"date":532,"type":41},"2026-04-02",{"date":534,"type":23},"2026-08-01",{"date":536,"type":23},"2027-12-01",{"name":436,"class":48},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":19,"minAge":545,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":24,"phases":547,"briefSummary":548,"conditions":549,"keywords":553,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":562,"leadSponsor":563,"locationsCount":82},"100629045","effects-of-an-aerobic-exercise-program-on-cardiovascular-risk-in-patients-with-chronic-kidney-disease-or-rheumatoid-arthritis-100629045","NCT07469540","Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arthritis","PARCA","Inclusion Criteria:\n\n* Diagnosis of Chronic Kidney Disease (CKD) or Rheumatoid Arthritis (RA), with no other risk factors related to the disease.\n* Having a glomerular filtration rate between 45 and 20 ml\u002Fmin\u002F1.73 m², corresponding to stages III and IV not on dialysis for patients with CKD ; or have a DAS 28 score ≥ 2.6 points for patients with RA.\n* Have a medical certificate stating that there are no adverse reactions to physical activity.\n* Affiliation with a French social security scheme or beneficiary of such a scheme.\n\nExclusion Criteria:\n\n* Unstabilised corticosteroid therapy and\u002For \\>10mg prednisone\u002Fday\n* Uncontrolled high blood pressure\n* Pregnant women\n* Impaired higher functions making it impossible to understand and adhere to an aerobic exercise program\n* Inability to perform physical exercise, regardless of the cause (neurological, central or peripheral, cardiovascular or respiratory, or musculoskeletal)\n* Legal incapacity or limited legal capacity\n* Subject unlikely to cooperate with the study and\u002For low cooperation anticipated by the investigator\n* Subject without health insurance\n* Subject is in the exclusion period of another study involving human subjects that may interfere with the results of this study, particularly by affecting inflammatory status and the cardiovascular system.","50 Years",{"count":478,"type":23},[26],"The goal of this clinical trial is to determine whether an aerobic exercise program can reduce cardiovascular risk in patients with systemic inflammation, such as those with rheumatoid arthritis and chronic kidney disease.\n\nThe main questions this study aims to address are:\n\n* Does an individualized aerobic exercise program reduce cardiovascular risk, as assessed arterial stiffness and endothelial function ?\n* What are the effects of this exercise program on inflammation and immunosenescence?\n\nResearchers will compare an individualized aerobic exercise program with a therapeutic education program (consisting of educational phone calls only) and a control group with no intervention.\n\nParticipants will:\n\n* Perform three physical activity sessions per week for six weeks (45-minute sessions at 60-80% of heart rate reserve);\n* Attend clinic visits at baseline, after the 6-week intervention, and at a 6-week follow-up after the intervention;\n* Undergo assessments including pulse wave velocity, hyperemic reactivity, and blood analyses.",[550,551,552,30],"Aerobic Exercise","Rhumatoid Arthisis","Chronic Kidney Disease",[554,555,556,557],"Systemic Inflammation","Arterial Stiffness","Hyperemic reactivity","Blood analyses","2026-03-10",{"date":560,"type":41},"2026-03-13",{"date":272,"type":23},{"date":134,"type":23},{"name":564,"class":48},"Jérôme Bouchan",{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":18,"sex":19,"minAge":199,"maxAge":173,"enrollmentInfo":573,"targetDuration":4,"studyType":24,"phases":575,"briefSummary":576,"conditions":577,"keywords":580,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":589,"leadSponsor":591,"locationsCount":82},"100626778","physical-inactivity-among-patients-with-cardiovascular-risk-100626778","NCT07440056","Physical Inactivity Among Patients With Cardiovascular Risk","Physical Inactivity Among Patients With Cardiovascular Risk: Proportion, Associated Factors, Perceived Barriers, and Effectiveness of an Intervention for Improvement at Government Primary Medical Care Institutions in Gampaha District","INSPIRE-PA","Inclusion Criteria:\n\n1. Patients permanently residing in Gampaha district for six months or more\n2. Patients registered and followed up at medical clinics in the same state sector PMCIs in Gampaha district, for a duration of three months or more\n\nExclusion Criteria:\n\n1. Pregnant mothers with any intermediate risk factor of chronic NCDs, followed up at state PMCIs in Gampaha district\n2. Patients diagnosed with atherosclerotic cardiovascular disease (ASCVD) (e.g. Coronary heart disease, Cerebrovascular disease, Peripheral artery disease, Aortic atherosclerotic disease) followed up at state sector primary medical care institutions in Gampaha district.\n3. Patients already diagnosed and on treatment for diabetes mellitus, any type of cancer and any chronic respiratory disease (e.g. Asthma, chronic obstructive pulmonary disease) followed up at state sector primary medical care institutions in Gampaha district, as their physical activity level and their knowledge on it may have changed following the diagnosis\n4. Patients with impaired cognitive functions (confirmed with medical records), as they are unable to report accurate responses independently.\n5. Patients who have undergone any surgical procedure within the last three months (confirmed by clinical documentation)\n6. Patients who have had any debilitating illness during the preceding week limiting their physical activity during the period of illness\n7. Patients who plan to change\u002Fchange their place of residence or shift their treatment follow-up from a state-sector PMCI to the private sector or any other treatment modality (e.g: Ayurveda) within the next six months",{"count":574,"type":23},192,[26],"The goal of this clinical trial is to learn if newly developed intervention package works to improve physical activity level among patients with intermediate cardiovascular risk factors. The main questions it aims to answer are:\n\nDoes the INSPIRE-PA intervention increase the level of physical activity among participants with intermediate cardiovascular risk factors?\n\n* What changes occur in physical activity level, BMI and blood pressure following participation in the intervention?\n* Are there any challenges, barriers, or unintended effects experienced by participants during the intervention period?\n* Researchers will compare the INSPIRE-PA intervention to usual care to determine whether the empowerment-based strategy is effective in improving physical activity levels and reducing cardiovascular risk among patients attending government primary medical care Iinstitutions.\n\nParticipants will:\n\n* Participate in the INSPIRE-PA program for 6 months\n* Attend scheduled follow-up visits at the primary medical care institution (e.g., every 2-4 weeks)for counselling, evaluation of physical activity level, and assessment of cardiovascular risk indicators\n* Engage in structured physical activity as recommended in the intervention package\n* Record their daily physical activity and any challenges or barriers in a physical activity logbook or diary\n* Undergo periodic measurements such as blood pressure, weight, waist circumference, and other relevant clinical assessments",[578,30,579],"Physical Activities","Empowerment",[581,582,583,584],"Physical activity","primary care","behavioural intervention","level of physical activity improvement","2026-02-24",{"date":587,"type":41},"2026-02-27",{"date":530,"type":23},{"date":590,"type":23},"2026-09-30",{"name":592,"class":48},"University of Colombo",{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":597,"acronym":598,"eligibilityCriteria":599,"healthyVolunteers":18,"sex":19,"minAge":59,"maxAge":4,"enrollmentInfo":600,"targetDuration":4,"studyType":24,"phases":602,"briefSummary":603,"conditions":604,"keywords":605,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":4},"100623951","the-effect-of-water-physical-exercise-program-in-thermal-water-and-hydropinotherapy-on-cardiovascular-health-100623951","NCT07403305","The Effect of Water Physical Exercise Program in Thermal Water and Hydropinotherapy on Cardiovascular Health","WPEPH","Inclusion Criteria:\n\n* Men or women\n* Age: \\>45 years\n* Written informed consent prior to participation\n* Physical condition suitable for participating in physical exercise activities\n* Controlled health conditions\n\nExclusion Criteria:\n\n* History of chronic or severe diseases that may affect study outcomes or limit study participation, such as:\n* Decompensated cardiovascular disease, renal insufficiency, or severe liver disease\n* Conditions preventing the ability in physical activity (e.g., severe respiratory issues, reduced mobility, severe arthritis)\n* Severe psychiatric or cognitive disorders that could affect comprehension or adherence to the study\n* Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or corticosteroids\n* Pregnancy or lactation\n* Less than 80% attendance at the 16-week aquatic exercise program",{"count":601,"type":23},80,[26],"The goal of this randomized four-arm clinical trial is to determine the effect of 16-week water physical exercise program in thermal water and hydroponotherapy on lipide profile in middle-aged and elderly people, with controlled health conditions.\n\nParticipants will be randomizate into four arms:\n\n* Arm I: Control\n* Arm II: Water Physical Exercise Program (WPEP) in thermal water\n* Arm III: Hydropinotherapy with thermal water combined with bay leaf (L. nobilis)\n* Arm IV: WPEP in thermal water and hydropinotherapy with thermal water combined with bay leaf (L. nobilis)\n\nPrimary outcome:\n\n1. Lipid profile (cholesterol total, low-density lipoprotein cholesterol (c-LDL), high-density lipoprotein cholesterol (c-HDL), triglycerides)\n\n   Secondary parameters:\n2. Inflammatory biomarkers: interleukin-6 (IL-6), C-reactive protein (CRP)\n3. Glucose metabolisc: fasting plasma glucose, insulin, Hemoglobin A1c (HbA1c)\n4. Aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase, bilirubin, creatinine.\n5. Anthropometric and clinical variables: weight, waist to hip ratio, body composition and bone mineral density\n6. Systolic and diastolic blood pressure\n7. Physical function\n8. Lifestyle parameters: sleep quality, quality of life and eating habits",[30],[606,607,608,609,32],"Thermal Water","Water Exercise","Hydropinotherapy","Lipid Profile","2026-02-04",{"date":612,"type":41},"2026-02-11",{"date":614,"type":23},"2026-01-19",{"date":616,"type":23},"2026-10-31",{"name":618,"class":48},"Instituto Politécnico de Bragança",{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":625,"eligibilityCriteria":626,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":391,"enrollmentInfo":627,"targetDuration":4,"studyType":24,"phases":628,"briefSummary":629,"conditions":630,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":4},"100621936","effects-of-sweetener-consumption-on-risk-factors-for-heart-disease-in-prediabetic-subjects-100621936","NCT07377097","Effects of Sweetener Consumption on Risk Factors for Heart Disease in Prediabetic Subjects","Effects of Sweetener Consumption on Risk Factors for Heart Disease","Sweetheart","Inclusion Criteria:\n\n* Presence of prediabetes (HbA1c 5.7-6.4% or glucose after oral glucose tolerance test 140 to 199 mg\u002FdL)\n* Written informed consent available\n\nExclusion Criteria:\n\n* Inability to communicate sufficiently in the required language\n* Dementia or other significantly cognitively impairing condition\n* Current pregnancy or breastfeeding\n* Other severe internal, neurological, or psychiatric condition\n* History of gout\n* History of gallstones \u002F diagnosis of cholelithiasis",{"count":601,"type":23},[26],"The aim of this prospective interventional study is to investigate the metabolic effects of consuming artificial and natural sweeteners in persons with prediabetes. Prediabetes is a condition characterized by blood sugar levels that are elevated above normal but not yet meeting the criteria for type 2 diabetes. This condition markedly increases the risk of progressing to type 2 diabetes, which in turn can lead to complications including cardiovascular diseases.\n\nArtificial sweeteners such as saccharin and sucralose, as well as natural sugar substitutes like erythritol, are increasingly used as alternatives to sugar and are recommended for individuals at cardiometabolic risk - including overweight individuals, patients with prediabetes, or diabetics - to help reduce caloric intake. Recent literature has reported possible negative associations between artificial sweeteners and blood sugar regulation in healthy subjects (1). Additionally, effects on various blood cells have been observed. For example, erythritol has been shown to alter platelet function leading to increased reactivity in healthy study participants following consumption (2).\n\nHowever, the impact of alternative sweeteners on metabolic processes and their effects on blood coagulation in patients with prediabetes-a population at increased risk-has not been systematically studied. In this planned interventional study, 80 patients meeting laboratory criteria for prediabetes will be randomly assigned to one of four groups, each receiving a different intervention for two weeks: saccharin, sucralose, erythritol, or a control group receiving water. The doses reflect the acceptable daily intake or known doses that are considered safe.\n\nAfter enrollment, participants will visit the study center 2 times: before starting the intervention and after completing the intervention. During these visits, biological samples such as blood, urine, and stool will be collected to study metabolism, gut bacteria, immune and blood cell function. Tests will include an oral glucose tolerance test, coagulation tests, and additional blood analyses. Additionally, participants will wear a glucose monitor to track blood sugar fluctuations during the intervention.\n\nThe investigators hypothesize that consumption of alternative sweeteners negatively affects blood sugar regulation and insulin sensitivity in patients with prediabetes. Furthermore, this study will explore how the candidate sweeteners influence the gut microbiome, blood cells and other metabolic factors in this population.",[631,632,633,634,635,30,636,637,638,639,640],"Prediabetic State","Metabolic Syndrome","Insulin Resistance","Thrombosis","Hypercoagulable State","Cardiovascular Risk Factors","Cardiovascular Diseases (CVD)","Prediabetes","Prediabetes \u002F Type 2 Diabetes","Sweeteners","2026-01-22",{"date":643,"type":41},"2026-01-29",{"date":645,"type":23},"2026-01-05",{"date":647,"type":23},"2026-11-01",{"name":649,"class":48},"Charite University, Berlin, Germany",{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":654,"acronym":655,"eligibilityCriteria":656,"healthyVolunteers":18,"sex":57,"minAge":20,"maxAge":4,"enrollmentInfo":657,"targetDuration":659,"studyType":62,"phases":4,"briefSummary":660,"conditions":661,"keywords":664,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":668,"lastUpdatePostDateStruct":669,"startDateStruct":671,"completionDateStruct":673,"leadSponsor":674,"locationsCount":82},"100620376","cardiovascular-risk-assessment-in-young-women-after-index-pregnancy-with-and-without-placental-complications-100620376","NCT07356817","Cardiovascular Risk Assessment in Young Women After Index Pregnancy With and Without Placental Complications","CARDIOMOM","Inclusion Criteria:\n\n* Patients who participated in the BiSC (Barcelona Life Study Cohort), EuroPE (Randomized open-label control trial to evaluate if the incorporation of sFlt1\u002FPlGF ratio in the diagnosis and classification of PE improves maternal and perinatal outcomes in women with suspicion of the disease; PI16\u002F00375) and AngioCor (Cardiac dysfunction and remodeling in patients with preeclampsia regulated by antiangiogenic environment: clinical and experimental approach, PI19\u002F00702) cohort studies\n* Who have delivered within the previous 3-6 years.\n* Give written consent when invited to participate in this study protocol.\n\nExclusion Criteria:\n\n* Unwillingness to participate in this study\n* Probability of loss to follow-up.",{"count":658,"type":23},1260,"1 Day","In this project, the investigators aim to study how all these factors determine the cardiovascular status of a total of 1,800 mothers, 3 to 6 years after delivery. In addition, the investigators want to assess whether lifestyle and living conditions after childbirth may improve or worsen this imprint, since women often prioritize their families over themselves, making it more difficult to maintain a healthy lifestyle that could reduce their cardiovascular risk. Furthermore, the investigators will evaluate how environmental exposures influence their health, as well as explore potential strategies for prediction and prevention.\n\nThe goal is to develop an easy-to-use algorithm or test that allows women and their physicians to assess this risk, ideally in the form of a mobile app. Although predictive algorithms for cardiovascular health already exist, most have been developed using predominantly male or older populations, and none have taken into account pregnancy-related events or environmental exposure - both of which are key determinants of women's cardiovascular health.",[30,662,663],"Preeclampsia (PE)","Fetal Weight",[665,666,667],"preeclampsia","Cardiovascular Risk","app","2026-01-12",{"date":670,"type":41},"2026-01-21",{"date":672,"type":41},"2023-08-28",{"date":134,"type":23},{"name":675,"class":48},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":677,"slug":678,"hasResults":12,"nctId":679,"briefTitle":680,"officialTitle":681,"acronym":682,"eligibilityCriteria":683,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":173,"enrollmentInfo":684,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":686,"conditions":687,"keywords":690,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":700,"lastUpdatePostDateStruct":701,"startDateStruct":703,"completionDateStruct":705,"leadSponsor":706,"locationsCount":49},"100611969","diet-and-cardiometabolism-in-rosario-100611969","NCT07247487","Diet and Cardiometabolism in Rosario","Comparative Analysis of Diet and Cardiometabolic Health in Individuals Following Vegan, Vegetarian, and Omnivorous Diets in the City of Rosario","DiCaMeR","Inclusion Criteria:\n\n* Adults aged 18 to 65 years.\n* Residence in the city of Rosario or surrounding areas.\n* Without major diseases.\n* BMI \\>18.5 and \\\u003C30.\n* Adherence to a vegan, vegetarian, or omnivorous diet for at least 1 consecutive year at the time of recruitment.\n\nExclusion Criteria:\n\n* Acute or chronic diseases (cancer, infections, heart disease, or others), gastrointestinal disorders affecting diet, diabetes mellitus, chronic kidney or liver disease, or any other condition that could affect study outcomes.\n* Food allergies or intolerances that substantially affect the individual's usual diet.\n* Pregnant or breastfeeding women.\n* High-performance athletes (\\>15 hours per week of high-intensity physical activity).\n* Use of medications that could affect study outcomes, including antihypertensives, lipid-lowering drugs, hypoglycemic agents, glucocorticoids, and anti-obesity drugs. Note: vitamin, mineral, or other dietary supplements are not exclusion criteria.\n* Problematic use of alcohol or other drugs.\n* Simultaneous participation in another clinical trial.\n* Inability (physical or psychological) to perform the procedures required by this study.\n* Blood transfusions within the last 3 months.",{"count":685,"type":23},105,"The DiCaMeR study is an observational, cross-sectional study aimed at evaluating the relationship between dietary patterns and cardiometabolic health in adults. The study includes adults following vegan, vegetarian, and omnivorous diets residing in Rosario, Argentina. Participants undergo comprehensive assessments including dietary intake, anthropometric measurements, body composition, blood pressure, grip strenght, and laboratory biomarkers related to cardiovascular and metabolic health. The main objective is to compare diet characteristics and cardiometabolic risk profiles across different dietary patterns, providing insights into the potential health benefits and risks associated with each dietary pattern.",[30,688,689],"Nutrition","Cardiometabolic Health Indicators",[691,692,693,694,695,696,697,688,698,699],"Vegan","Vegetarian","Plant-based","Cardiometabolic health","Cardiometabolism","Cardiovascular health","Diet","Dietary Patterns","Nutrients","2025-11-25",{"date":702,"type":41},"2025-12-03",{"date":704,"type":23},"2025-12-01",{"date":536,"type":23},{"name":707,"class":48},"Universidad del Centro Educativo Latinoamericano"]